THE COMPARATIVE EFFICACY OF INCLISIRAN, PCSK9 INHIBITING MONOCLONAL ANTIBODIES, AND EZETIMIBE FOR THE TREATMENT OF HIGH CHOLESTEROL IN ADULTS WITH OR AT RISK OF ASCVD: A SYSTEMATIC LITERATURE REVIEW AND NETWORK META-ANALYSIS
Campbell C, Desai N, Electricwala B, Stoekenbroek R, Kuang Y, Nevo A, Chang H, Uyei J, Cristino J. THE COMPARATIVE EFFICACY OF INCLISIRAN, PCSK9 INHIBITING MONOCLONAL ANTIBODIES, AND EZETIMIBE FOR THE TREATMENT OF HIGH CHOLESTEROL IN ADULTS WITH OR AT RISK OF ASCVD: A SYSTEMATIC LITERATURE REVIEW AND NETWORK META-ANALYSIS. Journal Of The American College Of Cardiology 2022, 79: 1551. DOI: 10.1016/s0735-1097(22)02542-6.Peer-Reviewed Original ResearchCOST-EFFECTIVENESS OF INCLISIRAN IN ATHEROSCLEROTIC CARDIOVASCULAR PATIENTS WITH ELEVATED LOW-DENSITY LIPOPROTEIN CHOLESTEROL DESPITE STATIN USE: A THRESHOLD ANALYSIS
Campbell C, Desai N, Electricwala B, Constanti M, Trueman D, Woodcock F, Cristino J. COST-EFFECTIVENESS OF INCLISIRAN IN ATHEROSCLEROTIC CARDIOVASCULAR PATIENTS WITH ELEVATED LOW-DENSITY LIPOPROTEIN CHOLESTEROL DESPITE STATIN USE: A THRESHOLD ANALYSIS. Journal Of The American College Of Cardiology 2022, 79: 1559. DOI: 10.1016/s0735-1097(22)02550-5.Peer-Reviewed Original Research